The Next Step Toward a Global AIDS Vaccine

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

The Next Step Toward a Global AIDS Vaccine

Science (11/25/94) Vol. 266, No. 5189, P. 1335
Koff, Wayne C.

There are four important areas where increased public sector efforts to facilitate private sector product development initiatives could significantly advance the timetable for the development of a safe and globally effective AIDS vaccine. First, incentives must be provided for expanded biopharmaceutical investment in AIDS vaccine development. Second, an international regulatory consensus of criteria for licensure of an effective AIDS vaccine must be established. Third, international capabilities of evaluating the efficacy of the best potential AIDS vaccines need to be expanded. Finally, mechanisms to facilitate information flow to vaccine manufacturers should be improved. These efforts, as well as an effective financing plan to maximize worldwide vaccine delivery and minimize lag periods between vaccine development and widespread distribution, would significantly accelerate the potential for development of a successful AIDS vaccine.

941223
AD942305

Copyright © 1994 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.